Preclinical data show HT-4253 reduces neuroinflammation and tau pathology; a second details a Phase 2a biomarker trial in pre-symptomatic APOE4 carriers via UAE genomics.

Purchase orders from multiple contract manufacturing customers have a combined value of more than $3.2M.

CAP accreditation is widely recognized as a mark of laboratory quality and operational excellence.

Brand consolidation strengthens Renew’s ability to move advanced molecular technologies from discovery to clinical implementation.

KyphoLift is gaining attention as hospitals and imaging centers prepare for federal accessibility requirements.

Marks an important milestone with a ribbon-cutting ceremony celebrating the completion of an expansive new distribution center.

Trial Reports 99% Successful Occlusion of Flow with 40 Investigators Delivering the New Embolic Through 20 Different Catheters.

Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnostics.